Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis
RCT (n=1704) found percentage of patients who had ACR20 response at week 12 was significantly higher with 15-mg or 30-mg upadacitinib than with placebo. (70.6% and 78.5% vs. 36.2%, respectively; p<0.001) but adverse events were more frequent with upadacitinib.
Source:
New England Journal of Medicine
SPS commentary:
Secondary end points included comparisons of upadacitinib with adalimumab, in which 65.0% on adalimumab had an ACR20 response at week 12. Both upadacitinib doses were noninferior to adalimumab for the ACR20 response at week 12. The incidence of adverse events through week 24 was 66.9% with 15-mg upadacitinib, 72.3% with 30-mg upadacitinib, 59.6% with placebo, and 64.8% with adalimumab.